Cargando…
Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I
Background: Spinal muscular atrophy (SMA) is a neuromuscular progressive disease, characterized by decreased amounts of survival motor neuron (SMN) protein, due to an autosomal recessive genetic defect. Despite recent research, there is still no cure. Nusinersen, an antisense oligonucleotide acting...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658131/ https://www.ncbi.nlm.nih.gov/pubmed/34884240 http://dx.doi.org/10.3390/jcm10235540 |
_version_ | 1784612657599348736 |
---|---|
author | Mirea, Andrada Shelby, Elena-Silvia Axente, Mihaela Badina, Mihaela Padure, Liliana Leanca, Madalina Dima, Vlad Sporea, Corina |
author_facet | Mirea, Andrada Shelby, Elena-Silvia Axente, Mihaela Badina, Mihaela Padure, Liliana Leanca, Madalina Dima, Vlad Sporea, Corina |
author_sort | Mirea, Andrada |
collection | PubMed |
description | Background: Spinal muscular atrophy (SMA) is a neuromuscular progressive disease, characterized by decreased amounts of survival motor neuron (SMN) protein, due to an autosomal recessive genetic defect. Despite recent research, there is still no cure. Nusinersen, an antisense oligonucleotide acting on the SMN2 gene, is intrathecally administered all life long, while onasemnogene abeparvovec-xioi, a gene therapy, is administered intravenously only once. Both therapies have proven efficacy, with best outcomes obtained when administered presymptomatically. In recent years, disease-modifying therapies such as nusinersen and onasemnogene abeparvovec-xioi have changed the natural history of SMA. Methods: We observed seven SMA type I patients, who received both therapies. We compared their motor function trajectories, ventilation hours and cough assist sessions to a control group of patients who received one therapy, in order to investigate whether combination therapy may be more effective than a single intervention alone. Results: Patients who received both therapies, compared to the monotherapy cohort, had the same motor function trajectory. Moreover, it was observed that the evolution of motor function was better in the 6 months following the first therapy than in the first 6 months after adding the second treatment. Conclusions: Our results suggest that early treatment is more important than combined therapy. |
format | Online Article Text |
id | pubmed-8658131 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86581312021-12-10 Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I Mirea, Andrada Shelby, Elena-Silvia Axente, Mihaela Badina, Mihaela Padure, Liliana Leanca, Madalina Dima, Vlad Sporea, Corina J Clin Med Article Background: Spinal muscular atrophy (SMA) is a neuromuscular progressive disease, characterized by decreased amounts of survival motor neuron (SMN) protein, due to an autosomal recessive genetic defect. Despite recent research, there is still no cure. Nusinersen, an antisense oligonucleotide acting on the SMN2 gene, is intrathecally administered all life long, while onasemnogene abeparvovec-xioi, a gene therapy, is administered intravenously only once. Both therapies have proven efficacy, with best outcomes obtained when administered presymptomatically. In recent years, disease-modifying therapies such as nusinersen and onasemnogene abeparvovec-xioi have changed the natural history of SMA. Methods: We observed seven SMA type I patients, who received both therapies. We compared their motor function trajectories, ventilation hours and cough assist sessions to a control group of patients who received one therapy, in order to investigate whether combination therapy may be more effective than a single intervention alone. Results: Patients who received both therapies, compared to the monotherapy cohort, had the same motor function trajectory. Moreover, it was observed that the evolution of motor function was better in the 6 months following the first therapy than in the first 6 months after adding the second treatment. Conclusions: Our results suggest that early treatment is more important than combined therapy. MDPI 2021-11-26 /pmc/articles/PMC8658131/ /pubmed/34884240 http://dx.doi.org/10.3390/jcm10235540 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mirea, Andrada Shelby, Elena-Silvia Axente, Mihaela Badina, Mihaela Padure, Liliana Leanca, Madalina Dima, Vlad Sporea, Corina Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I |
title | Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I |
title_full | Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I |
title_fullStr | Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I |
title_full_unstemmed | Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I |
title_short | Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I |
title_sort | combination therapy with nusinersen and onasemnogene abeparvovec-xioi in spinal muscular atrophy type i |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658131/ https://www.ncbi.nlm.nih.gov/pubmed/34884240 http://dx.doi.org/10.3390/jcm10235540 |
work_keys_str_mv | AT mireaandrada combinationtherapywithnusinersenandonasemnogeneabeparvovecxioiinspinalmuscularatrophytypei AT shelbyelenasilvia combinationtherapywithnusinersenandonasemnogeneabeparvovecxioiinspinalmuscularatrophytypei AT axentemihaela combinationtherapywithnusinersenandonasemnogeneabeparvovecxioiinspinalmuscularatrophytypei AT badinamihaela combinationtherapywithnusinersenandonasemnogeneabeparvovecxioiinspinalmuscularatrophytypei AT padureliliana combinationtherapywithnusinersenandonasemnogeneabeparvovecxioiinspinalmuscularatrophytypei AT leancamadalina combinationtherapywithnusinersenandonasemnogeneabeparvovecxioiinspinalmuscularatrophytypei AT dimavlad combinationtherapywithnusinersenandonasemnogeneabeparvovecxioiinspinalmuscularatrophytypei AT sporeacorina combinationtherapywithnusinersenandonasemnogeneabeparvovecxioiinspinalmuscularatrophytypei |